Neoantigen-Based Cancer Immunotherapy: One Step Closer to the Promise of Personalized Medicine
Back Bay analyzed companies involved in neoantigen therapy development for our white paper, Neoantigen-based cancer immunotherapy: One step closer to the promise of personalized medicine by Michelle Hoffmann, Peter Bak, and our oncology team. The paper details the promise of neoantigens to unlock the power of the immune system and eliminate specific tumor types. It also highlights some of the companies driving a groundswell of emerging therapeutics that harness a neoantigen approach. We take a close look at therapies that use bioengineering to make new cells in the lab, machine learning to develop personalized treatments, and approaches that modify the patient’s own cells.
Event date: June 22, 2018
Back Bay Senior Consultant, Tejdeep Singh Bawa has been invited for the second year to mentor, judge, and guide members of Princeton’s University Graduate Consulting Club through the 2018 PuGCC Case Competition.
On June 22, 2018 twenty-four teams of graduate and professional students interested in management consulting will show their expertise and creative thinking and learn high-level consulting skills from seasoned experts in the field, including Back Bay Life Science Advisors, McKinsey & Company, Accenture, and Boston Consulting Group.
Event date: June 1-5, 2018
Back Bay joined the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, where thousands of oncology professionals from around the world gathered to share the latest approaches to cancer care.
Event date: June 4-7, 2018
The Back Bay team, led by Chris Leo, Greg Benning, and Vasilios M. Kofitsas welcomed the 2018 Bio International Convention to our hometown of Boston. Boston’s trajectory as a biotech leader has been remarkable, and we’re proud to be part of the biotech and med tech evolution here. BIO brings together thousands from biopharma, med tech and more for collaborative discussion, networking and partnering opportunities.
Immuno-oncology, a promise for decades, has burst forth as a clear means to advance patient care and spur research and development. Science and industry are working fervently to untangle this data-heavy, rapidly-evolving field and bring effective IO combinations to more patients. As positive data and widespread support accumulate for the potential checkpoint inhibitors and neoantigens in numerous challenging and refractory cancers, hundreds of trials are being implemented that seek to increase efficacy and bring these novel therapeutics to more patients in critical need.
By Ned Benning, Analyst, Back Bay Life Science Advisors
One of the primary axioms at Back Bay Life Science Advisors is that assets must find the right form of capital. Venture is not right for every academic-derived technology. Going public is not right for every growing company or late-stage biotech. Geographic variation can bring different timelines, different IRR hurdles, and different ecosystem mandates. Capital sources are forever shifting, and lately, investment from China has been looming large on the radar screen for U.S. biotech. We see this as a good thing. (more…)
By Tejdeep Singh Bawa, Michelle Hoffmann, Susan Thompson, Stephanie Kwei
Medical device companies developing next-generation mitral valve repair and replacement technologies have generated unprecedentedly high valuations at ever-earlier stages of device development. Medtech investors are acquiring early-stage transcatheter mitral valve technologies long before commercialization and even before critical clinical data is amassed.
Boston, May 1, 2018—Back Bay Life Science Advisors, strategic and transactional advisors to the life science industry, announced today that Jonathan P. Gertler, Managing Partner and CEO, has been selected to judge the Start-up Stadium competition at the upcoming BIO International Convention (BIO 2018) June 4-7 in Boston.
Back Bay CEO and Denmark’s Consul General Interviewed on Bloomberg Radio about the Boston and Denmark Biotech Ecosystems
Bloomberg’s Anne Mostue spoke with Dr. Jonathan Gertler of Back Bay Life Sciences Advisors and Anne Dorte Riggelsen, Denmark’s Consul General in New York, about the synergies between Denmark and Boston in the life sciences field.
Listen to the Bloomberg interview here https://bloom.bg/2rjEY3J
2018 Transactional Trends: Key Issues for Cross-Border Deals; Focus on Emerging and Mid-Size Companies
By Greg Benning
Back Bay Life Science Advisors recently co-hosted DKBIO 2018: Danish Science & The City at Harvard Medical School focused on cross-border investment and transactions in the life sciences sector.
Back Bay’s M&A team presented information on the IPO, M&A and Venture markets, with a specific focus on mid-size companies, that finds clear shifts in money flow, M&A, IPOs, and VC investing volumes, as well as top-10 rankings.